rosiglitazone has been researched along with Weight Loss in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (52.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, P; Gupta, LP; Kumar, A; Rahuja, N; Sharma, S; Srivastava, AK; Srivastava, SP; Tamrakar, AK | 1 |
| Anker, SD; Doehner, W; Lainscak, M; Palus, S; Springer, J; Trobec, K; Tschirner, A; von Haehling, S | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Au, WS; Chow, BK; He, ML; Ko, OK; Kung, HF; Lin, MC; Liu, CC; Lu, LW; Ng, SS; Tam, S; Yeung, CM | 1 |
| Asp, ML; Belury, MA; Tian, M; Wendel, AA | 1 |
| Blüher, M; Catalán, V; Fernández-Real, JM; Frühbeck, G; Gómez-Ambrosi, J; Martínez-Barricarte, R; Moreno-Navarrete, JM; Ortega, FJ; Ricart, W; Rodríguez de Cordoba, S; Sabater, M | 1 |
| Artis, DR; Bollag, G; Erbe, DV; Gareski, T; Gartrell, K; Harding, K; Ibrahim, PN; Jalenak, M; Kubasiak, D; Lin, JJ; Mansour, TS; Panza, D; Perreault, M; Saiah, E; Tobin, JF; Vlasuk, GP; Wang, S; Will, S; Womack, P | 1 |
| Swanson, A; Watrin, K; Wilder, L | 1 |
| Al-Jebawi, AF | 1 |
| Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N | 1 |
| Asp, ML; Belury, MA; Kliewer, KL; Tian, M | 1 |
| Arslanian, S; Copeland, K; Cuttler, L; Hirst, K; Kaufman, F; Linder, B; Nathan, DM; Pyle, L; Tollefsen, S; Wilfley, D; Zeitler, P | 1 |
| Bøgelund, M; Ericsson, Å; Jendle, J; Nilsen, B; Ridderstråle, M; Torffvit, O | 1 |
| Koc, M; Kovácová, Z; Kracmerová, J; Langin, D; Malisová, L; Rossmeislová, L; Siklová-Vítková, M; Stich, V; Tencerová, M; Viquerie, N | 1 |
| Hällsten, K; Huupponen, R; Janatuinen, T; Knuuti, J; Lönnqvist, F; Lönnroth, P; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, T; Virtanen, KA | 1 |
| Marescaux, J; Rubino, F | 1 |
| Dufour, JF; Oneta, CM | 1 |
| Brunani, A; Caumo, A; Graci, S; Liuzzi, A; Margarini, C; Viberti, GC | 1 |
| Caputi, AP; Catalano, P; Crimi, N; Cuzzocrea, S; Di Paola, R; Genovese, T; Mastruzzo, C; Mazzon, E; Sortino, M; Thiemermann, C; Vancheri, C | 1 |
| Abbasi, F; Chang, SA; Chu, JW; Ciaraldi, TP; Lamendola, C; McLaughlin, T; Reaven, GM; Reaven, PD | 1 |
| Reblin, T; Rosak, C; Seidel, DK; Stammer, H; Standl, E | 1 |
| Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G | 1 |
| Atkin, SL; Cho, LW | 1 |
| Anderson, JW; Frederich, RC; Konz, EC; Reynolds, LR | 1 |
5 review(s) available for rosiglitazone and Weight Loss
| Article | Year |
|---|---|
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Disease Progression; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Prediabetic State; Rosiglitazone; Thiazolidinediones; Weight Loss | 2010 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Review Literature as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2011 |
[Alcoholic and non-alcoholic steatohepatitis].
Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver, Alcoholic; Gemfibrozil; Hepatitis; Hepatitis, Alcoholic; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Liver Transplantation; Middle Aged; Obesity; Pilot Projects; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography; Ursodeoxycholic Acid; Weight Loss | 2004 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss | 2007 |
4 trial(s) available for rosiglitazone and Weight Loss
| Article | Year |
|---|---|
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Failure; Weight Loss | 2012 |
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Topics: Adipose Tissue; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lactates; Lipids; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Weight Loss | 2003 |
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Obesity; Obesity, Morbid; Rosiglitazone; Thiazolidinediones; Weight Loss | 2008 |
Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.
Topics: Biomarkers; Blood Pressure; Body Constitution; Body Mass Index; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Obesity; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Loss | 2002 |
16 other study(ies) available for rosiglitazone and Weight Loss
| Article | Year |
|---|---|
Synthesis of propiophenone derivatives as new class of antidiabetic agents reducing body weight in db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Eating; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Mice; Mice, Inbred C57BL; Propiophenones; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Sprague-Dawley; Rats, Wistar; Streptozocin; Weight Loss | 2012 |
Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia.
Topics: Adipose Tissue; Animals; Body Composition; Body Fluid Compartments; Cachexia; Cardiac Output; Disease Models, Animal; Heart; Hypoglycemic Agents; Male; Muscle, Skeletal; Neoplasms; Random Allocation; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Ventricular Function, Left; Weight Loss | 2014 |
Pluronic L-81 ameliorates diabetic symptoms in db/db mice through transcriptional regulation of microsomal triglyceride transfer protein.
Topics: Animals; Carrier Proteins; Cell Line; Cholesterol; Diabetes Mellitus, Experimental; Drinking; Eating; Gene Expression Regulation; Humans; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Poloxamer; Rosiglitazone; Surface-Active Agents; Thiazolidinediones; Triglycerides; Weight Loss | 2009 |
Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice.
Topics: Adenocarcinoma; Adiponectin; Animals; Autophagy; Blood Glucose; Cachexia; Colonic Neoplasms; Crosses, Genetic; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Muscle, Skeletal; Muscular Atrophy; Neoplasm Proteins; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-akt; Random Allocation; Rosiglitazone; Thiazolidinediones; Weight Loss | 2010 |
Complement factor H is expressed in adipose tissue in association with insulin resistance.
Topics: Adipose Tissue; Complement Factor B; Complement Factor H; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Omentum; Organ Specificity; Reference Values; Rosiglitazone; Skin; Thiazolidinediones; Weight Loss; White People | 2010 |
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.
Topics: Animals; Appetite Depressants; Appetite Regulation; Energy Metabolism; Insulin Resistance; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Loss | 2010 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Remission Induction; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2010 |
Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.
Topics: Adipose Tissue; Animals; Anorexia; Blood Glucose; Cachexia; Eating; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Mice; Muscle Strength; Neoplasms; Organ Size; Proteolysis; Rosiglitazone; Thiazolidinediones; Weight Loss | 2011 |
Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Topics: Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Disease Management; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2012 |
Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile.
Topics: Adipocytes; Adipogenesis; Adiponectin; Cells, Cultured; Chemokine CCL2; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-8; Leptin; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Weight Loss | 2013 |
Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.
Topics: Anastomosis, Surgical; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Duodenum; Eating; Follow-Up Studies; Gastric Bypass; Glucose Tolerance Test; Jejunum; Male; Obesity; Probability; Random Allocation; Rats; Rats, Inbred Strains; Reference Values; Rosiglitazone; Thiazolidinediones; Weight Loss | 2004 |
Revised vs original QUICKI index during diet + rosiglitazone treatment in obese subjects.
Topics: Body Mass Index; Diet, Reducing; Humans; Hypoglycemic Agents; Insulin Resistance; Monitoring, Physiologic; Obesity; Rosiglitazone; Thiazolidinediones; Weight Loss | 2004 |
Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.
Topics: Analysis of Variance; Animals; Benzhydryl Compounds; Biopsy; Bleomycin; Epoxy Compounds; Immunoenzyme Techniques; Instillation, Drug; Male; Mice; Nitric Oxide Synthase; Peroxidase; Poly(ADP-ribose) Polymerases; Prostaglandin D2; Pulmonary Fibrosis; Random Allocation; Rosiglitazone; Thiazolidinediones; Tyrosine; Weight Loss | 2005 |
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes.
Topics: Adiponectin; Aged; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Multiprotein Complexes; Rosiglitazone; Thiazolidinediones; Weight Loss | 2006 |
Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Weight Loss | 2006 |
Preventing diabetes, Part II: an action plan.
Topics: Diabetes Mellitus; Diet; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Rosiglitazone; Smoking; Thiazolidinediones; Weight Loss | 2007 |